Free Sale Certificate Legalization for Jordan Medical Device Registration

1. Key takeaways

The Free Sale Certificate (FSC) performs two roles in Jordanian registration: first, it is the core document of the alternative route (where no CE or FDA certificate exists, the home-country FSC plus a reference-country FSC); second, it is the foundational document for opening the manufacturer file (the AR submits the manufacturer’s FSC in the JFDA system to establish the overseas manufacturer record). GRZAN’s conclusion is that, whichever route is taken, the FSC is a mandatory submission.

• Second conclusion: the FSC must be the original or a recently issued, duly notarised copy. FSCs issued to Chinese manufacturers usually require notarisation and, further, consular legalisation, a process that typically takes 4 to 6 weeks (practical estimate).
• Third conclusion: the time cost of the FSC must be moved to the very front of the project plan. It determines whether the Cosmo appointment can be requested and whether the original documents can be submitted in person; it is the starting switch of the entire chain.

2. Legal basis

The requirements governing the submission of the Free Sale Certificate and its role in the alternative route derive from the instruments listed below, each shown with its reference, publication date and the location of the relevant provisions.

Provision numbers are subject to the Arabic originals published in the Jordanian Official Gazette and issued by the JFDA; the 4-to-6-week figure is a practical estimate for the notarisation and consular legalisation process.

3. Expert insights

The observations below draw on GRZAN’s handling of FSC issuance, notarisation and consular legalisation for manufacturers entering the Jordanian market.

Insight 1: the FSC must be issued by the regulator or an authorised body of the country of origin. Jordan requires the “free sale certificate of the country of origin”, that is, a document proving that the product is lawfully marketed in the country of origin. A self-declaration issued by the company cannot substitute for it. A regulator-issued document also carries the issuing authority’s own accountability, which a self-declaration cannot replicate.

Insight 2: the reference-country FSC is the second pillar of the alternative route. Where the country of origin is not on the reference-country list (Switzerland, Australia, Japan, Canada, Norway), the company must provide, in addition to the home-country FSC, an FSC from any one of the above reference countries. The reference-country list shows variation across interpretations (some interpretations include the United Kingdom), so the list should be re-verified through the AR before submission (practical estimate).

Insight 3: notarisation and consular legalisation are two separate procedures. Notarisation addresses the formal authenticity of the document, while consular legalisation addresses its extraterritorial effect in Jordan. In practice, the FSC and the letter of authorisation usually require consular legalisation by the Jordanian embassy in the country of origin, with a process of about 4 to 6 weeks (practical estimate). Treating the two procedures as one continuous task, rather than as two separate ones, is what keeps the timeline honest.

Insight 4: the validity of the FSC must cover the review cycle. For the same reason as with ISO 13485, an FSC that expires during the review will produce a failed precondition. GRZAN recommends holding a remaining validity of no less than 6 months (practical estimate).

Insight 5: the FSC is bound to the manufacturer record. After the AR submits the manufacturer’s FSC in the JFDA system, the overseas manufacturer record is established. All subsequent product registrations for that manufacturer are attached to this record. This means the content of the FSC (manufacturer name, address, product scope) must remain consistent with all subsequent application documents. A discrepancy discovered at this point forces corrections across every later document, so GRZAN verifies the FSC wording against the master data before the AR submits anything.

4. Practical recommendations

• First, place FSC processing at position zero of the project plan. Start the issuance and legalisation of the FSC at the same time as the selection of the AR is being completed. Starting the paperwork while the AR selection closes is what keeps position zero meaningful.
• Second, verify the consistency between the FSC content and the subsequent applications. The manufacturer name and address should be fully identical to those in the other documents, so as to avoid a request for correction caused by name discrepancies. Because the manufacturer record is created once and reused, this consistency check pays for itself across the whole portfolio.
• Third, reserve 4 to 6 weeks for notarisation and consular legalisation (practical estimate). Where the project has a hard deadline, an expedited channel should be considered.
• Fourth, when taking the FSC alternative route, process the reference-country FSC in parallel. The legalisation processes for the two FSCs can proceed simultaneously. Running the two processes in parallel is what keeps the alternative route from falling behind the main route.

5. Verification checklist

• □ Confirmed that the FSC is issued by the regulator or an authorised body of the country of origin
• □ Confirmed that the FSC is the original or a recently issued, duly notarised copy
• □ 4 to 6 weeks reserved for notarisation and consular legalisation (practical estimate)
• □ The manufacturer name and address on the FSC checked as identical to the subsequent application documents
• □ If the alternative route is taken, the reference-country FSC processed in parallel and the list interpretation re-verified with the AR
• □ The remaining validity of the FSC checked against the review cycle
• □ The cited provision numbers have been re-verified against the Arabic text of the Official Gazette

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Jordanian market. Our team prepares JFDA-compliant dossiers, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com